Member Info for Jace86

Also consider though, what's the next RNS likely to look like and is this the bottom?

Last few posts have been more reasoned and without emotion, this is the tech we prefer. 👍

It depends on the amount of blood taken. I'd assume that you wouldn't need a second taking. The first sample should be enough. Using Bio-Technes platform it's fairly quick.

A competent technician would run them in the necessary batches anyway and I'd expect there to be some kind of procedure indicating how the test should be run.

It's still cheap and gives a better indicator.

For reference, grail costing about a grand a go and has less than coin toss odds unless someone's already dying of stage 4.

Pay attention to set A though and understand that you can run multiple tests at the necessary thresholds to rule in or rule out as necessary.

We all either buy or sell based on what we know or perceive to understand.

We all buy and sell based on our own timescales. Some are much longer than others.

I'm not sure why people need to argue over the above points.

Who are we trying to convince? We all have different beliefs on price and potential because we have different view points on timescale.

It's that simple.

Anything else is plain silly.

And DGreen - agree with your points on specificity and sensitivity. Good posts like yours just end up lost in noise.

Don't care. This is CIZ.

I see we are all still going in hard on the CDT angle...

I can understand if you are in VELA... It's a one trick pony.

Here though, it just screams that you want to drag the price down.

I agree, I don't think it's binary and wonder if there will be a pursuit of a listing or a further licensing strategy tie up. Our stake will be very different under terms of a public listing if this on the table too.

For me it's then is there a knock on effect to the rest of the schedule? So the FDA approval and launch.

The question is how much and what are their next objectives?

Are they aiming to raise enough for an immediate public listing or huge marketing campaign or anything else?

This month or early next.

MOU should be converted to a contract.

Christie's in Manchester are also recruiting for someone to take the lead with reducing times on cancer diagnosis.

The tightness of this share is what will feed it upwards. We will have sellers at various levels once the MOU becomes signed, FDA submission comes in and then approval.

Onwards to 25p (100mil mcap approx) at this point. Maybe higher. If we are looking at an OBD style rise we shouldn't see an OBD style drop.

We simply don't have the cash burn and the test will be easier to market. Given it's accuracy and ease.

On Cizzle BIO and seems to be a posting from Sept last year?

Should be concluded at some point this month.

That's more cash in the bank.

FDA submission by Sept.

Approval by Nov.

Plenty of upside on this mcap.

For those not yet decided, last stock box interview and RNS are recommended.

Also quite sad though that at the same time, they can't see what's coming in the next few months...

A bit of patience and they can happily exit with a profit if they wish.

(Hint - look at OBD mcap on similar news.)

It looks like another firm set up to replace that. So the question is, who did SGCS sign that initial contract with.

If it's the phoenix as opposed to the dodo, then it's on SGCS. I assume conduit did their due diligence...

Excaliburs accounts continually poor and very late...

The two percent stake that Igraine holds is in an insolvent firm.

It's insolvent.

https://find-and-update.company-information.service.gov.uk/company/12414592

👏 good share Cymru.

Shame I wasn't there.

Hopefully the next one more of us pop to and have large grins on our faces...

I went to the BOU AGM a long time ago.

Vols (not vines)

Valuations for biotech firms often don't go the way of revenue multiplied by X. It's usually more.

I've seen firms not even generating a return go for 9 figures.

1000 tests per day is good for starters. If there is an at risk population of 14.2 million would it be unreasonable to suggest that we could hit at least ten percent of that?

I don't think that the tests take long to run in a lab either. Two maybe three hours.

It's then how many machines would a site have and what's the capacity of each and how many sites... That'll give us an idea of vines.